Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.

Item

http://www.wikidata.org/entity/Q38394272

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.

@en

type

Item

label

Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.

@en

prefLabel

Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.

@en

P1476

Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.

@en

P2093

Catherine Rioufol

http://www.w3.org/2001/XMLSchema#string

Gilles Salles

http://www.w3.org/2001/XMLSchema#string

P2860

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.

P304

569-578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2015.1028919

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Catherine Rioufol

P577

2015-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25818308

http://www.w3.org/2001/XMLSchema#string